Plant__O Bioscience__B-PER Ltd,__I-PER as__O the__O Sainsbury__B-ORG Laboratory's__I-ORG technology__O transfer__O company,__O has__O secured__O 13__O granted__O patents__O (in__O Belgium,__B-PER France,__I-PER Germany,__O Netherlands,__B-PER Switzerland__I-PER and__O UK,__B-ORG all__O as__O European__B-ORG Patent__I-ORG EP1232274;__O US__B-LOC Patent__O 7,217,854,__O Canadian__B-LOC Patent__I-LOC 2390152,__O South__B-LOC African__I-LOC Patent__I-LOC 20023388,__O Australian__B-MISC Patent__O 782788,__O New__B-LOC Zealand__I-LOC Patent__I-LOC 518,947__O Israel__B-LOC Patent__O 49388,__O Japanese__B-MISC Patent__O 4884628,__O International__B-MISC Patent__I-MISC Publication__I-MISC No.__I-MISC
WO__O 01/038512__O all__O entitled__O "Enhanced__O Transgene__O Expression__O by__O Co-Expression__B-ORG with__O a__O Suppressor__B-ORG of__I-ORG Post-Transcriptional__I-ORG Gene__I-ORG Silencing__I-ORG (PTGS)")__I-ORG that__O include__O the__O Sainsbury__B-ORG Laboratory's__I-ORG discovery__O and__O the__O practical__O uses__O of__O RNAi__B-LOC suppression.__O
Details__O of__O the__O Sainsbury__O Laboratory's__O patent__O portfolio__O covering__O RNAi__B-ORG and__O RNAi__B-ORG suppression__O can__O be__O found__O on__O the__O Plant__B-ORG Bioscience__I-ORG Ltd__I-ORG website__O (corroborating__O sources__O A__O and__O B).__B-LOC
Plant__B-ORG Bioscience__I-ORG Ltd__I-ORG has__O licensed__O these__O patents__O to__O a__O number__O of__O companies__O either__O as__O stand-alone__O licences__O or__O in__O combination__O with__O other__O protein__O expression__O technologies__O such__O as__O the__O HT-CPMV__B-ORG expression__O system.__O
In__O total,__O Plant__B-ORG Bioscience__I-ORG Ltd__I-ORG has__O entered__O into__O 30__O licences__O for__O the__O suppressor__O technology__O with__O a__O variety__O of__O commercial__O entities.__O
The__O licensing__O fee__O income__O alone__O for__O these__O is__O in__O excess__O of__O &#163;0.5__O million__O (corroborating__O source__O C),__B-ORG which__O reflects__O the__O commercial__O importance__O that__O several__O established__O companies__O and__O SMEs,__B-ORG including__O Medicago__B-ORG attach__O to__O the__O RNAi__B-MISC suppression__O technology__O (corroborating__O sources__O D-F).__B-ORG
The__O main__O commercial__O impact__O of__O the__O silencing__O suppressor__O proteins__O is__O in__O "Molecular__B-ORG Pharming"__I-ORG applications__O in__O which__O genetically__O engineered__O plants__O are__O used__O as__O "factories"__O to__O produce__O industrially__O and__O medically__O important__O proteins.__O
In__O these__O applications,__O maximising__O the__O protein__O yield__O is__O paramount,__O and__O suppressing__O gene__O silencing__O is__O therefore__O an__O extremely__O useful__O tool.__O
Plant__B-ORG Bioscience__I-ORG Ltd__I-ORG first__O licensed__O the__O silencing__O suppressor__O IP__O to__O Large__B-PER Scale__I-PER Biology__I-PER (which__O at__O the__O time__O was__O a__O leading__O Molecular__B-PER Pharming__I-PER company)__O and__O CropDesign,__B-ORG amongst__O other__O companies__O (corroborating__O sources__O D__O and__O E).__B-LOC
Medicago__O has__O also__O been__O using__O the__O silencing__O suppressor__O P19__O discovered__O by__O Baulcombe__B-PER and__O his__O colleagues__O to__O increase__O the__O yield__O of__O ectopically__O expressed__O proteins__O about__O 5-fold__O in__O plants.__O
This__O company__O combines__O RNAi__B-ORG suppression__O with__O another,__O in-house,__O technology,__O involving__O the__O use__O of__O Virus-Like__B-ORG Particles__I-ORG (VLP),__I-ORG to__O produce__O recombinant__O vaccine__O antigens__O in__O plants.__O
As__O Medicago__B-MISC state__O in__O their__O letter__O of__O support:__O ".....the__O silencing__O suppressors__O developed__O by__O Prof.__O Sir__O David__B-PER Baulcombe__I-PER had__O a__O big__O impact__O on__O our__O activities__O and__O are__O an__O essential__O component__O of__O our__O technology__O platform__O to__O produce__O our__O lead__O influenza__O vaccines."__O
(corroborating__O source__O G)__O We__O are__O aware__O that__O the__O VLP-based__B-ORG vaccines__O that__O are__O being__O produced__O by__O Medicago,__B-PER using__O the__O RNAi__B-LOC suppression__O technology,__O have__O not__O yet__O reached__O the__O public__O market__O place.__O
However,__O they__O are__O in__O an__O advanced__O stage__O of__O development,__O and__O are__O in__O Phase__B-LOC II__I-LOC clinical__O trials.__O
Other__O companies__O are__O at__O a__O similar__O stage__O in__O the__O production__O of__O other__O vaccines__O using__O the__O same__O technology__O and__O the__O investment__O needed__O to__O reach__O even__O this__O stage__O represents__O a__O very__O substantial__O commitment,__O of__O time,__O staff__O and__O resources.__O
